For more than five decades the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles has been committed to increasing cure rates and improving quality of survival for children, adolescents and young adults through outstanding clinical care, innovative research, academic excellence and global leadership.

The Institute—one of the largest and highest-ranked pediatric hematology, oncology, and transplantation and cellular therapy programs in the U.S.—cares for approximately 6,000 patients and conducts more than 30,000 outpatient visits every year.

The Cancer and Blood Disease Institute has been ranked among the top 10 pediatric cancer programs in the country by U.S. News & World Report every year since the rankings were launched in 2008.

The Institute’s Clinical Trials Program is one of the nation’s largest devoted to children with cancer and blood disorders and is home to multiple leading international pediatric consortia, including Children’s Hospital Acquired Thrombosis Network (CHAT), New Approaches to Neuroblastoma Therapy (NANT) and Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL), and is a member of 20 major clinical trials consortia. In 2019 the program enrolled 1,394 patients in 184 clinical trials.

**PROGRAMS AND CENTERS**

**Oncology**

The Oncology Section focuses on early diagnosis, innovative multidisciplinary treatment, quality of life and long-term follow-up for patients with cancer. Specialists use the latest technology for tumor surgery and reconstruction, employing minimally invasive techniques whenever possible. In addition, the Oncology Section is the only one in the U.S. with access to an inpatient pediatric rehabilitation unit on campus. The Institute’s specialty oncology services include:

- Leukemia and Lymphoma Program
- Bone and Soft Tissue Tumors Program (including sarcoma)
- Neuro-oncology Program
- Neuroblastoma Program
- Radiation Oncology Program
- Retinoblastoma Program

The Leukemia and Lymphoma Program includes one of the largest chimeric antigen receptor (CAR) T-cell therapy programs in the U.S. treating children and young adults with relapsed and refractory leukemia and lymphomas.

The Radiation Oncology Program is one of only three dedicated freestanding pediatric programs in the country and includes onsite state-of-the-art facilities and equipment.

**Hematology**

The Hematology Section treats 750 patients annually with a wide variety of blood disorders including sickle cell disease, thalassemia, aplastic anemia, hemophilia and epidermolysis bullosa. Physicians, nurse practitioners, clinical nurses, social workers and other caregivers offer patients and families expertise, counseling and education in health maintenance, nutrition and pain management.
Transplantation and Cellular Therapy
The Transplantation and Cellular Therapy Program performs nearly 100 blood and marrow transplants annually, including autologous and allogeneic transplants from family and unrelated donor marrow, cord blood and peripheral blood progenitor cells. Additional areas of expertise include cell therapy, immunotherapy, reduced toxicity approaches and alternative donor transplantation. The Cellular Therapy Program conducts a wide variety of cellular therapy clinical trials including CAR T-cell and natural killer (NK) cells for pediatric cancers and gene therapies for hemoglobinopathies.

Survivorship and Supportive Care Program
The Survivorship and Supportive Care (SSC) Program offers a broad array of psychosocial clinical services aimed at improving quality of life for our patients and families during and after treatment. Part of the SSC Program, the HOPE Behavioral Health, Neuropsychology and Education Service provides psychosocial support and education to patients and families. The Medical Supportive Care Service advances care that reduces side effects and other negative consequences of cancer, serious blood diseases and their treatments.

ACCOLADES AND ACHIEVEMENTS
The Cancer and Blood Disease Institute offers hope, healing and leading-edge care for patients and families. Our experts are saving lives every day while working to make scientific discoveries that will help improve survival rates and quality of life for children around the world.

• The Institute treats many of the sickest children and has one of the highest survival rates among the top 10 pediatric cancer programs in the nation for germ cell, hepatoblastoma, leukemia, medulloblastoma and neuroblastoma.

• Children’s Hospital Los Angeles is a founding member of CureWorks, an international collaboration designed to accelerate the development of immunotherapy treatments for childhood cancer. The Institute is pioneering the use of cellular immunotherapies for children with cancer who have exhausted other curative options. The Institute treats a large number of complex CAR-T cases, with a 97% survival rate at 100 days post treatment.

• The Institute’s commitment to optimizing the patient and family experience is reflected in the results of surveys conducted by the National Research Council, which placed Children’s Hospital Los Angeles among the top three pediatric hospitals in the nation for patient and family satisfaction, including No. 1 for inpatient services.

• The American Society for Radiation Oncology Accreditation Program for Excellence has recognized the Radiation Oncology Program for delivering high-quality patient care. Children’s Hospital Los Angeles is the first and only freestanding children’s hospital to receive this honor.